DHEA: the last elixir.
(1) DHEA, or dehydroepiandrosterone, is an adrenal steroid. Its physiological role is unclear, but it is known to be an intermediate in sex hormone synthesis. DHEA replacement therapy is not currently indicated in adrenal insufficiency. (2) Plasma DHEA levels are so low in most animal species that they are difficult to measure, hindering studies of the impact of DHEA on ageing. Most animal studies are based on administration of pharmacological doses. (3) Clinical data have been obtained in a very large number of observational studies, in which plasma concentrations of DHEA were measured in various situations. The only established fact is that circulating concentrations show wide interpersonal variability and a tendency to fall with age. Low DHEA levels have not so far been linked to any specific health disorders. (4) Clinical trials of DHEA have focused on cognitive function, well-being, libido, immunostimulation, etc. There is no proof that DHEA is beneficial in these areas. (5) The side effects of DHEA are linked to its androgenic effects (acne, hirsutism), its unfavourable effects on lipid metabolism (a cardiovascular risk factor), and a possible growth-stimulating effect on hormone-dependent malignancies (prostate, breast). (6) In practice, there is currently no scientific reason to prescribe DHEA for any purpose whatsoever.
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000172:deficiency / Q000493:pharmacokinetics / Q000627:therapeutic use; D000309:Adrenal Insufficiency / Q000188:drug therapy; D000367:Age Factors; D000368:Aged; D000375:Aging / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D002986:Clinical Trials as Topic; D003687:Dehydroepiandrosterone / Q000009:adverse effects / Q000172:deficiency / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D003687:Dehydroepiandrosterone